Table 3.
Differences in overall survival associated with immunotherapy in age by subgroups.
| Participants, no. | Pooled HR (95% CI) for ICI vs. controlled therapies | Test for difference | ||||
|---|---|---|---|---|---|---|
| Variable | Studies, no. | <65 | ≥65 | <65 | ≥65 | P value |
| Overall | 18 | 7092 | 5715 | 0.74 (0.68, 0.81) | 0.80 (0.75, 0.86) | 0.17 |
| Line of therapy | ||||||
| First | 11 | 4286 | 3561 | 0.74 (0.65, 0.85) | 0.80 (0.73, 0.87) | 0.351 |
| Subsequent | 7 | 2806 | 2154 | 0.73 (0.64, 0.83) | 0.80 (0.69, 0.92) | 0.367 |
| Intervention therapy | ||||||
| ICI alone | 11 | 4268 | 3369 | 0.74 (0.66, 0.83) | 0.78 (0.72, 0.85) | 0.468 |
| ICI combined with non-ICI | 7 | 2824 | 2346 | 0.73 (0.63, 0.86) | 0.83 (0.74, 0.94) | 0.203 |
| Pathologic types | ||||||
| Squamous | 4 | 1112 | 973 | 0.69 (0.53, 0.91) | 0.82 (0.65, 1.05) | 0.358 |
| Nonsquamous | 5 | 2203 | 1664 | 0.74 (0.62, 0.88) | 0.77 (0.67, 0.87) | 0.72 |
Abbreviations: HR = hazard ratio; ICI = immune checkpoint inhibitor.